Table 1. Demographic characteristics.
| Sample size, N | 44 |
| Age, years | 63.3 ± 13.2 |
| Male, n (%) | 38 (86.4%) |
| BMI, (kg/m2) | 28.5 ± 4 |
| Hypertension, n (%) | 19 (43.2%) |
| Diabetes II, n (%) | 8 (18.2%) |
| CAD, n (%) | 15 (34.1%) |
| Heart failure, n (%) | 42 (95.5%) |
| NYHA classification | III (II–III) |
| CKD, n (%) | 11 (25%) |
| AF, n (%) | 16 (36.4%) |
| Type of VAs | |
| *PVC, n (%) | 7 (15.9%) |
| *VT, n (%) | 37 (84.1%) |
| ICM, n (%) | 11 (25%) |
| DCM, n (%) | 18 (40.9%) |
| HCM, n (%) | 3 (6.8%) |
| ARVC, n (%) | 5 (11.4%) |
| LVEDD, mm | 58 ± 7.9 |
| LVEF | 41.3 ± 12.9% |
| Beta-Blocker, n (%) | 37 (84.1%) |
| Amiodarone, n (%) | 30 (68.2%) |
| ACEI/ARB, n (%) | 22 (50%) |
| Spirolactone, n (%) | 15 (34.1%) |
| OACs, n (%) | 16 (36.4%) |
| ICD, or CRT-D, n (%) | 37 (84.1%) |
Notes.
- BMI
- body mass index
- CAD
- coronary artery disease
- NYHA
- New York Heart Association
- CKD
- chronic kidney disease
- AF
- atrial fibrillation
- VA
- ventricular arrhythmia
- PVC
- premature ventricular contraction
- VT
- ventricular tachycardia
- ICM
- ischemic cardiomyopathy
- DCM
- dilated cardiomyopathy
- HCM
- hypertrophic cardiomyopathy
- ARVC
- arrhythmogenic right ventricular cardiomyopathy
- LVEDD
- left ventricular end diastolic diameter
- LVEF
- left ventricular ejection fraction
- ACEI
- angiotensin-converting-enzyme inhibitor
- ARB
- angiotensin II receptor blocker
- OAC
- oral anticoagulation